Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Biomarkers 2014

Brit Mollenhauer's Biography

Brit Mollenhauer, Head of Clinical Research, Paracelsus-Elena-Klinik

Dr. Brit Mollenhauer graduated from Medical School at Georg-August University Goettingen, Germany in 2000. During residency training in Neurology from 2000-2005 in Goettingen, Dr. Mollenhauer was also a member of the National Creutzfeldt-Jakob Disease Surveillance Center under the mentorship of Prof. Sigrid Poser, where she focused her research activities on the differential diagnoses of prion diseases, with special interest on dementia with Lewy Bodies, Parkinson disease and cerebrospinal fluid biomarker in collaboration with Dres Jens Wiltfang and Markus Otto. After completing the neurology training in 2005 Dr. Mollenhauer received a research fellowship by the “Stifterverband fuer die Deutsche Wissenschaft” to visit Harvard University and laboratory of Dr. M. Schlossmacher in Boston, USA, where she studied biomarker development and cerebrospinal fluid alpha-synuclein (2005-2007). Since June 2007 she holds a position as Assistant Professor in Neurology at Georg-August University Goettingen, Germany and the Movement Disorder Paracelsus-Elena Klinik, Kassel (Prof. Claudia Trenkwalder). She established her own research team and focuses on human body fluid biomarker detection and assay development for improving diagnosis of movement disorders.
Brit Mollenhauer established a prospective longitudinal cohort of at enrolment 159 de novo PD subjects and 110 matched healthy controls (DeNoPa study) for biomarker studies. She is also member of the executive steering committee of the Parkinson’s Progression Marker Initiative (PPMI) of the Michael J. Fox Foundation.

Brit Mollenhauer Image

Biomarkers for Parkinson’s Disease: What has Been Achieved and What Needs to Come

Tuesday, 8 July 2014 at 14:15

Add to Calendar ▼2014-07-08 14:15:002014-07-08 15:15:00Europe/LondonBiomarkers for Parkinson’s Disease: What has Been Achieved and What Needs to ComeBiomarkers 2014 in Cambridge, UKCambridge,

An objective biomarker for Parkinson’s disease (PD) is urgently needed. The quantification of proteins (e.g., tau-protein, ß-amyloid and also a-synuclein) in cerebrospinal fluid (CSF) has been shown to be helpful even in the early clinical diagnosis.

Add to Calendar ▼2014-07-08 00:00:002014-07-09 00:00:00Europe/LondonBiomarkers 2014Biomarkers 2014 in Cambridge, UKCambridge,